Response to CD19-specific CAR T cells
| Characteristic . | Patients, % (n = 24) . |
|---|---|
| Complete response/complete response with incomplete count recovery (CR/CRi) (n) | 75 (18 of 24) |
| MRD− (in the CR cohort) | 89 (16 of 18) |
| Response/conditioning chemotherapy (n) | |
| Cyclophosphamide | |
| HD-Cy | 94 (15 of 16) |
| LD-Cy | 38 (3 of 8) |
| Fludarabine | |
| With fludarabine | 83 (5 of 6) |
| Without fludarabine | 72 (13 of 18) |
| Response/pretreatment disease burden | |
| Morphologic disease (≥5% BM blasts) | 50 (5 of 10) |
| MRD (<5% BM blasts) | 93 (13 of 14) |
| Characteristic . | Patients, % (n = 24) . |
|---|---|
| Complete response/complete response with incomplete count recovery (CR/CRi) (n) | 75 (18 of 24) |
| MRD− (in the CR cohort) | 89 (16 of 18) |
| Response/conditioning chemotherapy (n) | |
| Cyclophosphamide | |
| HD-Cy | 94 (15 of 16) |
| LD-Cy | 38 (3 of 8) |
| Fludarabine | |
| With fludarabine | 83 (5 of 6) |
| Without fludarabine | 72 (13 of 18) |
| Response/pretreatment disease burden | |
| Morphologic disease (≥5% BM blasts) | 50 (5 of 10) |
| MRD (<5% BM blasts) | 93 (13 of 14) |
Disease response for all patient treated and surviving more than 28 days after infusion (n = 24), MRD absence (MRD−) in patients who achieved response (n = 18), cohort response based on dose intensity of conditioning chemotherapy (HD-Cy vs LD-Cy; P = .01), and cohort response based on pretreatment disease burden (morphologic disease vs MRD; P = .05).